Crystallisation Process Development
As a world leader in pharmaceutical services, Almac delivers bespoke crystallisation development work programs for small molecules and peptides designed to provide a robust, scaleable, and transferrable crystallisation procedure to help accelerate clinical development and minimise risk in any downstream activities by eliminating batch-to-batch variability. The goals of typical studies include:
- Impurity rejection / purge studies
- Kinetics of nucleation and growth
- Polymorphic form control
- Maximising yield
- Morphology engineering studies
- Particle size control
- Bulk density and powder flow improvement
- Milling and micronisation studies
- Isolation and drying processes
- Control over residual solvent
- Seeding protocol
Read the full article below to learn more.View Resource
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.